Adimmunce in History

Home>Adimmunce in History

No.,

Date

Title

2007.12.24

Dr. Ho, clinically trained in internal medicine and infectious diseases, is a research fellow of the Academia Sinica and a professor of the National Taiwan University, Yang-Ming University, and National Defense University. With her interests focusing on translational research in vaccine-preventable diseases and emerging infectious diseases aiming for disease control and prevention, she also served on several consultative committees important to the national polices of disease control and preventions in Taiwan prior to joining Adimmune.

2006.4.11

U.S. FDA GMP COMPLIANCE WORKSHOP
April 11, 2006 - April 13, 2006

2005.11.7

"Establishment of cGMP Biopharmaceutical Manufacturing Facility - A Presentation of Twiwan Experience", Sy-Dar Wang, Ph.D., Chief Technical Officer, Adimmune Corporation, Taiwan & Wei-Kuang Chi, Ph.d., Director, cGMP Biopharmaceutical Plant Facility, Development Center for Biotechnology, Taiwan. BioProcess INTERNATIONAL ASIA PACIFIC CONFERENCE&EXHIBITION November 7-9,2005 * Shangri-La Hotel * Singapore

2005.01.25

Establishing the Foundation for the Biopharmaceutical
Industry of Taiwan.

2005.01.24

ADImmune Corp. / Kitasato Institute technology transfer &
factory design ceremony.

2004.08.01

The production capability for the influenza vaccine was expand to over 800 thousand doses per year.

2004.06.01

The shareholders meeting was held to elect the fourteenth Adimmune Corporate Board members.

2004.05.01

The developing plan for the Adimmune Second Corporate campus was completed.

The expansion of the packaging line and the remodeling of the classificed area for packaging processes were completed.

2004.03.01

A four million doses per year influenza vaccine manufacturing facility project was initiated.

The lease agreement for leasing Taiwan Sugar Cooperation’s land to build a biotechnology campus was signed.

2003.12.01

The Danish SSI passed a facility inspection required for the three phase validation .

2003.11.01

The company homepage and the of company related operations computerization were completed.

2003.09.01

Dr. Sydar Wang was recruited as the Chief Technical Officer.

2003.08.01

The production capability for the influenza vaccine was expanded to more than 600 thousand doses per year. The collaboration relationship of marketing the vaccine was established with Taiwan Biotech Co.,Ltd(Sin Tong Company) and the clinical trial (phase four) was conducted.

The development of the enterovirus vaccine was initiated. Professor Huan-Yao Lei from the Department of Microbiology and Immunology, College of Medicine, NCKU was contracted to conduct a study on animal models.

2003.05.01

The ADImmune Second corporate campus was preliminarily planned.

Amid the SARS outbreak, the company participated in the vaccine-developing project organized by the Academia Sinica and redesign R&D pilot plant to BL3 level.

The phase one personnel training for the CDC technology transfer was completed.

2003.02.01

The computerized process was actively conducted. The ERP system was introduced to handle the purchasing logistic processes.

2002.11.01

A collaboration contract for the technology transfer of vaccine products from to the Center for Disease Control was signed. The contract authorized the transfer of the technology from CDC to Adimmune.

The product license for purified tuberculin granted by government agency.

2002.10.01

The ADImmune Corporation / Kitasato influenza vaccine was formally licensed for marketing. The product won the bid of a government project to supply 358000 doses.

The nine cycles of internal control for the prepare of initial publicly offering was finalized and enforced amid the planned public offer.

2002.09.01

A pilot scale plasmid DNA production facility was initiated in the research and development laboratory. The project was planned since June 6, 2001.

2002.03.01

The first phase of the “Development of Japanese encephalitis vaccine (JEV) by Cell Culture technology” project completed.

The first phase of influenza vaccine technology transfer from Kitasato Institute was completed.

2002.01.10

The Ceremony for the Initiation of the New Manufacturing Facility construction was held on January 10, 2002.